See more : MINISTOP Co., Ltd. (9946.T) Income Statement Analysis – Financial Results
Complete financial analysis of Karyopharm Therapeutics Inc. (KPTI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Karyopharm Therapeutics Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Rianlon Corporation (300596.SZ) Income Statement Analysis – Financial Results
- Brookfield Infrastructure Partners L.P. (BIP-UN.TO) Income Statement Analysis – Financial Results
- Siam Food Products Public Company Limited (SFP.BK) Income Statement Analysis – Financial Results
- Abdullah Al-Othaim Markets Company (4001.SR) Income Statement Analysis – Financial Results
- Alwaha REIT Fund (9300.SR) Income Statement Analysis – Financial Results
Karyopharm Therapeutics Inc. (KPTI)
About Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 146.03M | 157.07M | 209.82M | 108.09M | 40.89M | 30.34M | 1.61M | 154.00K | 250.00K | 229.00K | 387.00K | 634.00K | 152.00K |
| Cost of Revenue | 4.94M | 5.21M | 3.40M | 2.71M | 2.41M | 161.37M | 107.27M | 86.94M | 97.74M | 60.13M | 28.45M | 14.10M | 0.00 |
| Gross Profit | 141.09M | 151.86M | 206.42M | 105.38M | 38.49M | -131.04M | -105.67M | -86.78M | -97.49M | -59.90M | -28.07M | -13.46M | 152.00K |
| Gross Profit Ratio | 96.62% | 96.68% | 98.38% | 97.50% | 94.11% | -431.95% | -6,583.68% | -56,353.25% | -38,997.60% | -26,156.33% | -7,251.94% | -2,123.19% | 100.00% |
| Research & Development | 138.75M | 148.66M | 160.84M | 150.81M | 122.34M | 161.37M | 107.27M | 86.94M | 97.74M | 60.13M | 28.45M | 14.10M | 8.62M |
| General & Administrative | 131.88M | 145.40M | 143.85M | 126.42M | 0.00 | 48.85M | 24.87M | 23.95M | 21.58M | 15.95M | 5.89M | 2.43M | 1.84M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 131.88M | 145.40M | 143.85M | 126.42M | 105.42M | 48.85M | 24.87M | 23.95M | 21.58M | 15.95M | 5.89M | 2.43M | 1.84M |
| Other Expenses | 0.00 | -83.00K | -85.00K | 206.00K | -50.00K | -33.00K | -81.00K | 10.00K | -2.00K | -27.00K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 270.63M | 294.06M | 304.69M | 277.23M | 227.76M | 210.22M | 132.14M | 110.89M | 119.33M | 76.08M | 34.34M | 16.52M | 10.46M |
| Cost & Expenses | 275.57M | 299.28M | 308.09M | 279.94M | 230.17M | 210.22M | 132.14M | 110.89M | 119.33M | 76.08M | 34.34M | 16.52M | 10.46M |
| Interest Income | 10.94M | 2.36M | 582.00K | 2.82M | 5.42M | 4.03M | 1.70M | 1.28M | 897.00K | 97.00K | 3.00K | 2.00K | 0.00 |
| Interest Expense | 23.82M | 25.00M | 26.05M | 27.14M | 15.65M | 2.49M | 0.00 | 0.00 | 0.00 | 1.00K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 530.00K | 621.00K | 789.00K | 972.00K | 974.00K | 735.00K | 713.00K | 717.00K | 634.00K | 323.00K | 144.00K | 122.00K | 83.00K |
| EBITDA | -118.42M | -139.31M | -96.99M | -167.85M | -182.93M | -175.15M | -128.21M | -108.72M | -118.44M | -75.45M | -33.80M | -15.77M | -10.23M |
| EBITDA Ratio | -81.09% | -89.08% | -46.60% | -156.20% | -449.72% | -579.80% | -8,133.21% | -71,903.90% | -47,630.40% | -33,089.96% | -8,772.61% | -2,486.75% | -6,728.95% |
| Operating Income | -129.54M | -142.20M | -98.27M | -171.85M | -189.28M | -179.88M | -130.54M | -110.73M | -119.08M | -75.85M | -33.95M | -15.89M | -10.31M |
| Operating Income Ratio | -88.71% | -90.53% | -46.84% | -159.00% | -462.85% | -592.97% | -8,133.21% | -71,903.90% | -47,630.40% | -33,120.52% | -8,772.61% | -2,506.31% | -6,783.55% |
| Total Other Income/Expenses | -13.24M | -22.72M | -25.55M | -24.11M | -10.28M | 1.50M | 1.62M | 1.29M | 895.00K | 69.00K | 3.00K | 2.00K | 0.00 |
| Income Before Tax | -142.78M | -164.92M | -123.82M | -195.96M | -199.55M | -178.38M | -128.92M | -109.44M | -118.18M | -75.78M | -33.95M | -15.89M | -10.31M |
| Income Before Tax Ratio | -97.77% | -105.00% | -59.01% | -181.31% | -487.98% | -588.02% | -8,032.46% | -71,063.64% | -47,272.40% | -33,090.39% | -8,771.83% | -2,505.99% | -6,783.55% |
| Income Tax Expense | 323.00K | 369.00K | 268.00K | 309.00K | 40.00K | 26.00K | 63.00K | 139.00K | -895.00K | -69.00K | -3.00K | -2.00K | 0.00 |
| Net Income | -143.10M | -165.29M | -124.09M | -196.27M | -199.59M | -178.41M | -128.98M | -109.58M | -118.18M | -75.78M | -33.95M | -15.89M | -10.31M |
| Net Income Ratio | -97.99% | -105.23% | -59.14% | -181.59% | -488.08% | -588.10% | -8,036.39% | -71,153.90% | -47,272.40% | -33,090.39% | -8,771.83% | -2,505.99% | -6,783.55% |
| EPS | -1.25 | -2.02 | -1.65 | -2.72 | -3.22 | -3.14 | -2.81 | -2.92 | -3.32 | -2.43 | -5.59 | -6.64 | -10.27 |
| EPS Diluted | -1.25 | -2.02 | -1.65 | -2.72 | -3.22 | -3.14 | -2.81 | -2.92 | -3.32 | -2.43 | -5.59 | -6.64 | -10.27 |
| Weighted Avg Shares Out | 114.22M | 81.87M | 75.22M | 72.04M | 61.96M | 56.78M | 45.90M | 37.52M | 35.62M | 31.14M | 6.07M | 2.39M | 1.00M |
| Weighted Avg Shares Out (Dil) | 114.22M | 81.87M | 75.22M | 72.04M | 61.96M | 56.78M | 45.90M | 37.52M | 35.62M | 31.14M | 6.07M | 2.39M | 1.00M |
Penny Stocks To Buy Now? 3 With Ratings Up To 1,742%
In a stock market characterized by growing unpredictability, traders are leaning on every possible resource. One such indispensable tool, whether dealing with penny stocks or more expensive shares, is the insight provided by analysts.
Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Tops Revenue Estimates
Karyopharm Therapeutics (KPTI) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.62 per share a year ago.
Karyopharm Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
– Achieved Second Quarter 2023 Total Revenue of $37.6 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $28.5 Million – – Maintains Full Year 2023 Total Revenue Guidance of $145 Million to $160 Million, Including U.S. XPOVIO Net Product...
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWTON, Mass. , Aug. 1, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 26,350 restricted stock units (RSUs) to 4 newly-hired employees.
Karyopharm to Report Second Quarter 2023 Financial Results on August 2, 2023
-- Conference Call Scheduled for Wednesday, August 2, 2023, at 8:00 a.m. ET -- NEWTON, Mass.
Karyopharm Announces Presentation of Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer
Signal of PFS Improvement in SIENDO for Selinexor-Treated Patients was Observed Only in Subgroup Who are TP53 Wild-Type with a Median Progression-Free Survival of 27.4 Months Median PFS Not Reached for Selinexor-Treated Patients Who are TP53 Wild-Type MSS (pMMR) Updated...
Karyopharm Announces Updated Exploratory Subgroup Analysis from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer to be Presented at ASCO Plenary Series on July 25th
- Data Provide Further Support for Company's Ongoing Phase 3 Study Evaluating Selinexor as Maintenance Therapy Following Systemic Therapy in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer - NEWTON, Mass. , July 19, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc....
Why Is Karyopharm Therapeutics (KPTI) Stock Up 21% Today?
Karyopharm Therapeutics (NASDAQ: KPTI ) stock is climbing higher on Tuesday after getting fast-track designation for its myelofibrosis treatment. The Food and Drug Administration (FDA) has granted fast-track designation to the development of selinexor.
Karyopharm Receives FDA Fast Track Designation for Selinexor for the Treatment of Myelofibrosis
– Regulatory Designation Includes Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis and Post-Polycythemia Vera Myelofibrosis – – Pivotal Phase 3 Study of Selinexor and Ruxolitinib in Treatment-Naïve Myelofibrosis Initiated in June 2023 – NEWTON, Mass. , July 17, 2023 /PRNewswire/ -- Karyopharm...
Antengene Announces XPOVIO® Regulatory Approval in Hong Kong for the Treatment of Relapsed and/or Refractory Multiple Myeloma
XPOVIO® (selinexor) is the first and only XPO1 inhibitor approved in Hong Kong XPOVIO® has received regulatory approvals in 41 countries and regions including the United States, Israel, the United Kingdom, the European Union (the 27 member countries including France...
Source: https://incomestatements.info
Category: Stock Reports